Strategic Roadmap and Financial Performance
Healthcare Platform | RHWC
Revenue | BHD MN
1.2
3.1
1.0
Financial and Operational Review | Period Ended 31st March 2022
Financial Performance
2x growth in revenue on the back of strong performance across IVF, Pediatrics and OBG
Significant narrowing of EBITDA losses to only BHD 0.1MN in 1Q-2022
Dental department launched, ongoing partnerships with key players in aesthetics and with visiting doctors
Reduced operating leverage through use of revenue share arrangements whilst facility remains in its ramp-up phase
0.5
Net Cash / (Debt)
FY20
FY21 I 1Q21
1Q22
Action Plan
EBITDA | BHD MN
(2.0)
I
(0.1)
(0.4)
Corporate
Strategy
(1.0)
FY20
FY21
1Q21
1Q22
Net Loss | BHD MN(2)
Corporate
Finance
BHD (7.1) MN(1)
Completed Initiative
Launch of the Cosmetology and Bariatrics departments
31 Mar. 2022
Ongoing Initiative
✓ Establish in-house laboratory service to improve lab referral volume and overall patient
experience
✓ Launch tie-ups with renowned physicians to perform procedures at RHWC on a visiting basis
✓ Expand offering to allow visiting consultants to perform surgical procedures on male patients
✓ Launch "Pediatric Centre of Excellence"
Repurpose existing space to allow addition of at least 5+ OP consultation rooms
Improve Working Capital Cycle
✓ Hire an independent management team to drive the Company through the next phase of growth
✓ Develop financial and operational KPIs to track Management performance
Corporate
Governance
(0.4)
(0.6)
✓ Obtain National Healthcare Regulatory Authority Accreditation
(2.0)
(3.0)
FY20
FY21
1Q21
1Q22
(1) Excluding lease liabilities of BHD 1.9 MN (2) Excluding finance costs associated with debt and shareholder funding
22View entire presentation